NFKB1 and diabetes mellitus: The daily oral gavage of 5 mg/kg calycosin can inhibit the IL-33/ST2 axis and lead to the substantial activation of the NF-κB inflammatory pathway and the TGF-β/Smad pathway while also activating the Nrf2/ARE pathway to attenuate diabetes-induced inflammation, renal fibrosis and oxidative stress in high fat diet-fed/STZ-injected rats [117].